

NOVEMBER 2004 DUR BOARD MEETING MINUTES

Date: November 17, 2004

Members Present: Eichler, Nagy, Harrison, Fitzgerald, Sargent, Bradley, Brown, Crichton, Cobb, Burton

Others Present: Peterson, Preshinger, Roger Citron RPh. (Medicaid), Barnhill (Drug PA), Renner (Mental Health Services), Pope, Daly (First Health), Interested members of the public and representatives of pharmaceutical manufacturers.

Mark Eichler opened the meeting with a review of meeting procedure.

Board Minutes: The minutes of the October meeting were reviewed with Mark asking the Board members to pay special attention to the PDL discussion results. The minutes were approved.

Department update:

Dan Peterson, Pharmacy Program Officer for DPHHS updated the board on the following:

The state plan amendment for the PDL is still pending with CMS. Chuck Hunter, Deputy Director of DPHHS is currently in Washington, DC working on this approval. Dan introduced Roger Citron to the Board. Roger, the new Pharmacist for DPHHS, will begin work at the department on December 6.

Old Business:

FACT trial information was discussed with Sherrill Brown leading the discussion. The Board consensus was no change in their previous PDL decision on Bisphosphonates.

The PA Unit has had some questions about high dose Zyprexa. Dr. Nagy and Carla Cobb agreed that the PA Unit should continue to require documentation from the physician for doses from 40 to 60 mg daily and doses over 60 mg need further review.

Preferred Drug List Discussion:

The following drug classes were considered and outcomes determined by review of the evidence, public comment, and then board discussion.

INHALED CORTICOSTEROIDS:

Pulmicort Respules and Advair have no alternatives so will be included on PDL

Must have as clinical alternatives- Pulmicort Turbuhaler or Flovent

Class Effect-All others

INTRANASAL STEROIDS:

Class Effect

LEUKOTRIENE MODIFIERS;

Must have-Singulair

May have-Accolate

SHORT-ACTING BETA2 ADRENERGIC AGENTS (Inhalers and Nebulizers):

Class Effect

LONG-ACTING BETA2 ADRENERGIC AGENTS :

Class Effect

SECOND GENERATION QUINOLONES:

Must have-Ciprofloxacin

Class Effect-All other agents

THIRD GENERATION QUINOLONES:

Class Effect- (Avelox, Tequin, Levaquin)

ORAL MACROLIDES:

Must have: Azithromycin (Zithromax), Clarithromycin (Biaxin), Erythromycin

The other classes on the agenda for this month will be reviewed at a later date to be announced on the web site.

No grandfathering will be allowed for any of the medications in these classes.

Next meeting is December 15, 2004 at The MACO Building meeting room in Helena.

Meeting adjourned at 4:30.